These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 1642448)
21. [Appraisal of activity in Crohn's disease. Value of inflammatory tests, deconjugation tests and the absorption of bile salts and alpha l-antitrypsin clearance]. Gillard C; Deflandre J; Brassinne A Acta Gastroenterol Belg; 1984; 47(3):309-16. PubMed ID: 6333769 [No Abstract] [Full Text] [Related]
22. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis. Becker K; Berger M; Niederau C; Frieling T Hepatogastroenterology; 1999; 46(28):2309-14. PubMed ID: 10521988 [TBL] [Abstract][Full Text] [Related]
24. Qualitative differences in faecal alpha-1-antitrypsin in patients with Crohn's disease. Colombel JF; Mizon C; Balduyck M; Cortot A Gut; 1989 Feb; 30(2):279-80. PubMed ID: 2784776 [No Abstract] [Full Text] [Related]
25. Enteric protein loss as a marker of intestinal inflammatory activity in Crohn's disease: comparability of enteric clearance and stool concentration of alpha-1-antitrypsin? Hundegger K; Stufler M; Karbach U Z Gastroenterol; 1992 Oct; 30(10):722-8. PubMed ID: 1441675 [TBL] [Abstract][Full Text] [Related]
26. Isolation and characterization of the viscous, high-molecular-mass microbial carbohydrate fraction from faeces of healthy subjects and patients with Crohn's disease and the consequences for a therapeutic approach. Ruseler-van Embden JG; Van Lieshout LM; Binnema DJ; Hazenberg MP Clin Sci (Lond); 1998 Oct; 95(4):425-33. PubMed ID: 9748418 [TBL] [Abstract][Full Text] [Related]
27. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease. Becker K; Niederau C; Frieling T Z Gastroenterol; 1999 Jul; 37(7):597-605. PubMed ID: 10458008 [TBL] [Abstract][Full Text] [Related]
28. alpha 1-Antitrypsin-levels and phenotypes in Crohn's disease in the Netherlands. Klasen EC; Biemond I; Weterman IT Gut; 1980 Oct; 21(10):840-2. PubMed ID: 6969207 [TBL] [Abstract][Full Text] [Related]
29. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Sugi K; Saitoh O; Hirata I; Katsu K Am J Gastroenterol; 1996 May; 91(5):927-34. PubMed ID: 8633583 [TBL] [Abstract][Full Text] [Related]
30. Endotoxaemia in patients with Crohn's disease: a longitudinal study of elastase/alpha 1-proteinase inhibitor and Limulus-amoebocyte-lysate reactivity. Fink PC; Suin de Boutemard C; Haeckel R; Wellmann W J Clin Chem Clin Biochem; 1988 Mar; 26(3):117-22. PubMed ID: 3260268 [TBL] [Abstract][Full Text] [Related]
31. [Blood protein concentrations--are they parameters of disease activity in Crohn's disease?]. Meryn S; Lochs H; Bettelheim P; Sertl K; Mulak K Leber Magen Darm; 1985 Jul; 15(4):160-4. PubMed ID: 3877229 [TBL] [Abstract][Full Text] [Related]
32. Quantification of fecal alpha 1-antitrypsin excretion for assessment of inflammatory bowel diseases. Becker K; Frieling T; Häussinger D Eur J Med Res; 1998 Feb; 3(1-2):65-70. PubMed ID: 9512970 [TBL] [Abstract][Full Text] [Related]
33. Simplified determination of intestinal protein excretion based on alpha 1-antitrypsin clearance. Karbach U; Singe CC; Ewe K Z Gastroenterol; 1988 Mar; 26(3):169-73. PubMed ID: 3261475 [TBL] [Abstract][Full Text] [Related]
34. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. King MB; Campbell EJ; Gray BH; Hertz MI Am J Respir Crit Care Med; 1994 Apr; 149(4 Pt 1):966-71. PubMed ID: 8143063 [TBL] [Abstract][Full Text] [Related]
36. [Carcinoembryonic antigen (CEA) levels and their clinical significance in Crohn's disease]. Meryn S; Lochs H; Francesconi M Wien Klin Wochenschr; 1983 Apr; 95(9):301-4. PubMed ID: 6604368 [TBL] [Abstract][Full Text] [Related]
37. Development and analytical validation of an enzyme-linked immunosorbent assay (ELISA) for the measurement of alpha(1)-proteinase inhibitor in serum and faeces from cats. Burke KF; Ruaux CG; Suchodolski JS; Williams DA; Steiner JM Res Vet Sci; 2012 Oct; 93(2):995-1000. PubMed ID: 22074688 [TBL] [Abstract][Full Text] [Related]
38. The antielastase screen of the lower respiratory tract of alpha 1-proteinase inhibitor-sufficient patients with emphysema or pneumothorax. Gast A; Dietemann-Molard A; Pelletier A; Pauli G; Bieth JG Am Rev Respir Dis; 1990 Apr; 141(4 Pt 1):880-3. PubMed ID: 2327650 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential. Mast AE; Salvesen G; Schnebli HP; Pizzo SV J Lab Clin Med; 1990 Jul; 116(1):58-65. PubMed ID: 2376698 [TBL] [Abstract][Full Text] [Related]
40. Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals. Krook A; Lindström B; Kjellander J; Järnerot G; Bodin L J Clin Pathol; 1981 Jun; 34(6):645-50. PubMed ID: 7251906 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]